|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Greenlee H, DuPont-Reyes MJ, Balneaves LG,
Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick
SM, et al: Clinical practice guidelines on the evidence-based use
of integrative therapies during and after breast cancer treatment.
CA Cancer J Clin. 67:194–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Runowicz CD, Leach CR, Henry NL, Henry KS,
Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge
SB, Jacobs LA, et al: American cancer society/American society of
clinical oncology breast cancer survivorship care guideline. J Clin
Oncol. 34:611–635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Starr DA, Saffery R, Li Z, Simpson AE,
Choo KH, Yen TJ and Goldberg ML: HZwint-1, a novel human
kinetochore component that interacts with HZW10. J Cell Sci.
113:1939–1950. 2000.PubMed/NCBI
|
|
5
|
Vos LJ, Famulski JK and Chan GK: hZwint-1
bridges the inner and outer kinetochore: Identification of the
kinetochore localization domain and the hZw10-interaction domain.
Biochem J. 436:157–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kops GJ, Kim Y, Weaver BA, Mao Y, McLeod
I, Yates JR III, Tagaya M and Cleveland DW: ZW10 links mitotic
checkpoint signaling to the structural kinetochore. J Cell Biol.
169:49–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang J, He D, Yang P, He J and Zhang Y:
Genome-wide expression profiling of glioblastoma using a large
combined cohort. Sci Rep. 8:151042018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J and
Zhao M: Identification of candidate biomarkers and analysis of
prognostic values in ovarian cancer by integrated bioinformatics
analysis. Med Oncol. 33:1302016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ying H, Xu Z, Chen M, Zhou S, Liang X and
Cai X: Overexpression of Zwint predicts poor prognosis and promotes
the proliferation of hepatocellular carcinoma by regulating
cell-cycle-related proteins. Onco Targets Ther. 11:689–702. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Endo H, Ikeda K, Urano T, Horie-Inoue K
and Inoue S: Terf/TRIM17 stimulates degradation of kinetochore
protein ZWINT and regulates cell proliferation. J Biochem.
151:139–144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pérez de Castro I, de Cárcer G and
Malumbres M: A census of mitotic cancer genes: New insights into
tumor cell biology and cancer therapy. Carcinogenesis. 28:899–912.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bieniek J, Childress C, Swatski MD and
Yang W: COX-2 inhibitors arrest prostate cancer cell cycle
progression by down-regulation of kinetochore/centromere proteins.
Prostate. 74:999–1011. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma XJ, Dahiya S, Richardson E, Erlander M
and Sgroi DC: Gene expression profiling of the tumor
microenvironment during breast cancer progression. Breast Cancer
Res. 11:R72009. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richardson AL, Wang ZC, De Nicolo A, Lu X,
Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S:
X chromosomal abnormalities in basal-like human breast cancer.
Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jézéquel P, Campone M, Gouraud W,
Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L:
bc-GenExMiner: An easy-to-use online platform for gene prognostic
analyses in breast cancer. Breast Cancer Res Treat. 131:765–775.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jézéquel P, Frénel JS, Campion L,
Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M:
bc-GenExMiner 3.0: New mining module computes breast cancer gene
expression correlation analyses. Database (Oxford).
2013:bas0602013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forbes SA, Beare D, Bindal N, Bamford S,
Ward S, Cole CG, Jia M, Kok C, Boutselakis H, De T, et al: COSMIC:
High-resolution cancer genetics using the catalogue of somatic
mutations in cancer. Curr Protoc Hum Genet. 91:10.11.1–10.11.37.
2016. View
Article : Google Scholar
|
|
22
|
Forbes SA, Beare D, Boutselakis H, Bamford
S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al:
COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids
Res. 45:D777–D783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Razavi P, Chang MT, Xu G, Bandlamudi C,
Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, et
al: The genomic landscape of endocrine-resistant advanced breast
cancers. Cancer Cell. 34:427.e6–438.e6. 2018. View Article : Google Scholar
|
|
26
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ,
et al: The somatic mutation profiles of 2,433 breast cancers
refines their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banerji S, Cibulskis K, Rangel-Escareno C,
Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY,
Sougnez C, Zou L, et al: Sequence analysis of mutations and
translocations across breast cancer subtypes. Nature. 486:405–409.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: The landscape of cancer genes and mutational processes
in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ciriello G, Gatza ML, Beck AH, Wilkerson
MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et
al: Comprehensive molecular portraits of invasive lobular breast
cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eirew P, Steif A, Khattra J, Ha G, Yap D,
Farahani H, Gelmon K, Chia S, Mar C, Wan A, et al: Dynamics of
genomic clones in breast cancer patient xenografts at single-cell
resolution. Nature. 518:422–426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lefebvre C, Bachelot T, Filleron T,
Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M,
Lacroix-Triki M, et al: Mutational profile of metastatic breast
cancers: A retrospective analysis. PLoS Med. 13:e10022012016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ivshina AV, George J, Senko O, Mow B,
Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al:
Genetic reclassification of histologic grade delineates new
clinical subtypes of breast cancer. Cancer Res. 66:10292–10301.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15:1222014. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ravindran Menon D, Luo Y, Arcaroli JJ, Liu
S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC,
et al: CDK1 interacts with Sox2 and promotes tumor initiation in
human melanoma. Cancer Res. 78:6561–6574. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei D, Parsels LA, Karnak D, Davis MA,
Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y and
Morgan MA: Inhibition of protein phosphatase 2A radiosensitizes
pancreatic cancers by modulating CDC25C/CDK1 and homologous
recombination repair. Clin Cancer Res. 19:4422–4432. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Whalley HJ, Porter AP, Diamantopoulou Z,
White GR, Castañeda-Saucedo E and Malliri A: Cdk1 phosphorylates
the Rac activator Tiam1 to activate centrosomal Pak and promote
mitotic spindle formation. Nat Commun. 6:74372015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY,
Chan ACY, Ma KW, Xia W and Cheung TT: Blocking CDK1/PDK1/β-Catenin
signaling by CDK1 inhibitor RO3306 increased the efficacy of
sorafenib treatment by targeting cancer stem cells in a preclinical
model of hepatocellular carcinoma. Theranostics. 8:3737–3750. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miller WR, Larionov AA, Renshaw L,
Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho
S, et al: Changes in breast cancer transcriptional profiles after
treatment with the aromatase inhibitor, letrozole. Pharmacogenet
Genomics. 17:813–826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cancello G, Maisonneuve P, Rotmensz N,
Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R,
Montagna E, Luini A, et al: Prognosis and adjuvant treatment
effects in selected breast cancer subtypes of very young women
(<35 years) with operable breast cancer. Ann Oncol.
21:1974–1981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Narod SA: Breast cancer in young women.
Nat Rev Clin Oncol. 9:460–470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Azim HA Jr, Michiels S, Bedard PL, Singhal
SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ,
Sotiriou C and Loi S: Elucidating prognosis and biology of breast
cancer arising in young women using gene expression profiling. Clin
Cancer Res. 18:1341–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han W and Kang SY; Korean Breast Cancer
Society, : Relationship between age at diagnosis and outcome of
premenopausal breast cancer: Age less than 35 years is a reasonable
cut-off for defining young age-onset breast cancer. Breast Cancer
Res Treat. 119:193–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Keegan TH, DeRouen MC, Press DJ, Kurian AW
and Clarke CA: Occurrence of breast cancer subtypes in adolescent
and young adult women. Breast Cancer Res. 14:R552012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bretones G, Delgado MD and León J: Myc and
cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wahlström T and Henriksson MA: Impact of
MYC in regulation of tumor cell metabolism. Biochim Biophys Acta.
1849:563–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fujiwara K, Yuwanita I, Hollern DP and
Andrechek ER: Prediction and genetic demonstration of a role for
activator E2Fs in Myc-induced tumors. Cancer Res. 71:1924–1932.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wu L, de Bruin A, Wang H, Simmons T,
Cleghorn W, Goldenberg LE, Sites E, Sandy A, Trimboli A, Fernandez
SA, et al: Selective roles of E2Fs for ErbB2- and Myc-mediated
mammary tumorigenesis. Oncogene. 34:119–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y,
Zhang T, Russo J, Cai C, Yuan X, et al: Positive feedback loop
mediated by protein phosphatase 1α mobilization of P-TEFb and basal
CDK1 drives androgen receptor in prostate cancer. Nucleic Acids
Res. 45:3738–3751. 2017.PubMed/NCBI
|
|
54
|
Saatci Ö, Borgoni S, Akbulut Ö, Durmuş S,
Raza U, Eyüpoğlu E, Alkan C, Akyol A, Kütük Ö, Wiemann S and Şahin
Ö: Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent
phosphorylation and inactivation of Bcl-2/xL in HER2-positive
breast cancer. Oncogene. 37:2251–2269. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Diril MK, Ratnacaram CK, Padmakumar VC, Du
T, Wasser M, Coppola V, Tessarollo L and Kaldis P: Cyclin-dependent
kinase 1 (Cdk1) is essential for cell division and suppression of
DNA re-replication but not for liver regeneration. Proc Natl Acad
Sci USA. 109:3826–3831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang P, Kawakami H, Liu W, Zeng X,
Strebhardt K, Tao K, Huang S and Sinicrope FA: Targeting CDK1 and
MEK/ERK overcomes apoptotic resistance in BRAF-mutant human
colorectal cancer. Mol Cancer Res. 16:378–389. 2018. View Article : Google Scholar : PubMed/NCBI
|
